TransMedics Reports Q3 2026 Record Revenue Growth Driven by National OCS Program
TransMedics Group (TMDX) reported strong third-quarter results for fiscal year 2026, with total revenue reaching $203 million, a 41% increase year-over-year. This growth was primarily fueled by increased liver and heart transplant volumes through the company's National OCS Program (NOP). Despite a 6% decline in overall U.S. disease donor volume, TransMedics successfully captured market share, particularly within its liver segment which generated $150 million in revenue. The company also demonstrated significant scaling of its logistics capabilities following the acquisition of PAD Aviation. While the aviation business caused some initial margin dilution, service revenue surged 60%. Looking ahead, TransMedics raised its full-year 2026 revenue guidance to a range of $764 million to $774 million and is preparing for international expansion into Italy, the Netherlands, and Belgium.
Tickers: $AAPL $AMZN $GOOG $META $MSFT $NVDA $TMDX $TSLA
Topics: Fiscal Guidance Net Income Organic Revenue Revenue Growth